Initially, we established three glioma cell lines stably expressing the IDH1R132H mutation based on wild‐type A172, SF295, and U87 cells, and confirmed enhanced D‐2‐hydroxyglutarate (D2HG) production in the IDHmt cells (Figure S3A,B, Supporting Information), which reliably recapitulated the biological outputs of clinical IDH mutations, including slower proliferation, migration, invasion, and colony formation (Figure S3C–F, Supporting Information). The gene discussed is IDH1; the disease is central nervous system cancer.